Cargando…

Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide

Although magnesium oxide is widely used as a laxative, alterations in serum magnesium concentrations among patients taking daily magnesium oxide have not been clarified. The present retrospective, cross-sectional study investigated the risk factors for hypermagnesemia in patients taking daily oral m...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Hideki, Suzuki, Hidekazu, Hirai, Yuichiro, Okuzawa, Anna, Kayashima, Atsuto, Kubosawa, Yoko, Kinoshita, Satoshi, Fujimoto, Ai, Nakazato, Yoshihiro, Nishizawa, Toshihiro, Kikuchi, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667383/
https://www.ncbi.nlm.nih.gov/pubmed/31379418
http://dx.doi.org/10.3164/jcbn.18-117
_version_ 1783440025013190656
author Mori, Hideki
Suzuki, Hidekazu
Hirai, Yuichiro
Okuzawa, Anna
Kayashima, Atsuto
Kubosawa, Yoko
Kinoshita, Satoshi
Fujimoto, Ai
Nakazato, Yoshihiro
Nishizawa, Toshihiro
Kikuchi, Masahiro
author_facet Mori, Hideki
Suzuki, Hidekazu
Hirai, Yuichiro
Okuzawa, Anna
Kayashima, Atsuto
Kubosawa, Yoko
Kinoshita, Satoshi
Fujimoto, Ai
Nakazato, Yoshihiro
Nishizawa, Toshihiro
Kikuchi, Masahiro
author_sort Mori, Hideki
collection PubMed
description Although magnesium oxide is widely used as a laxative, alterations in serum magnesium concentrations among patients taking daily magnesium oxide have not been clarified. The present retrospective, cross-sectional study investigated the risk factors for hypermagnesemia in patients taking daily oral magnesium oxide. Of 2,176 patients administered daily magnesium oxide, 193 (8.9%) underwent assays of serum magnesium concentrations and were evaluated. High serum magnesium concentration and hypermagnesemia were defined as serum magnesium concentrations ≥2.5 mg/dl and ≥3.0 mg/dl, respectively. Of the 193 patients taking daily magnesium oxide, 32 (16.6%) had high serum magnesium concentration and 10 (5.2%) had hypermagnesemia. Factors associated with hypermagnesemia included chronic kidney disease (CKD) grade 4 (p = 0.014) and magnesium oxide dosage (p = 0.009). Factors associated with high serum magnesium concentration included magnesium oxide dosage >1,000 mg/day (p = 0.004), CKD grades 4 (p = 0.000) and concomitant use of stimulant laxatives (p = 0.035). Age, however, was not associated with hypermagnesemia or high serum magnesium concentration. In conclusion, renal function and magnesium oxide dosage, but not age, were associated with hypermagnesemia and high serum magnesium concentration in patients with functional constipation taking daily magnesium oxide.
format Online
Article
Text
id pubmed-6667383
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher the Society for Free Radical Research Japan
record_format MEDLINE/PubMed
spelling pubmed-66673832019-08-02 Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide Mori, Hideki Suzuki, Hidekazu Hirai, Yuichiro Okuzawa, Anna Kayashima, Atsuto Kubosawa, Yoko Kinoshita, Satoshi Fujimoto, Ai Nakazato, Yoshihiro Nishizawa, Toshihiro Kikuchi, Masahiro J Clin Biochem Nutr Original Article Although magnesium oxide is widely used as a laxative, alterations in serum magnesium concentrations among patients taking daily magnesium oxide have not been clarified. The present retrospective, cross-sectional study investigated the risk factors for hypermagnesemia in patients taking daily oral magnesium oxide. Of 2,176 patients administered daily magnesium oxide, 193 (8.9%) underwent assays of serum magnesium concentrations and were evaluated. High serum magnesium concentration and hypermagnesemia were defined as serum magnesium concentrations ≥2.5 mg/dl and ≥3.0 mg/dl, respectively. Of the 193 patients taking daily magnesium oxide, 32 (16.6%) had high serum magnesium concentration and 10 (5.2%) had hypermagnesemia. Factors associated with hypermagnesemia included chronic kidney disease (CKD) grade 4 (p = 0.014) and magnesium oxide dosage (p = 0.009). Factors associated with high serum magnesium concentration included magnesium oxide dosage >1,000 mg/day (p = 0.004), CKD grades 4 (p = 0.000) and concomitant use of stimulant laxatives (p = 0.035). Age, however, was not associated with hypermagnesemia or high serum magnesium concentration. In conclusion, renal function and magnesium oxide dosage, but not age, were associated with hypermagnesemia and high serum magnesium concentration in patients with functional constipation taking daily magnesium oxide. the Society for Free Radical Research Japan 2019-07 2019-07-01 /pmc/articles/PMC6667383/ /pubmed/31379418 http://dx.doi.org/10.3164/jcbn.18-117 Text en Copyright © 2019 JCBN http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mori, Hideki
Suzuki, Hidekazu
Hirai, Yuichiro
Okuzawa, Anna
Kayashima, Atsuto
Kubosawa, Yoko
Kinoshita, Satoshi
Fujimoto, Ai
Nakazato, Yoshihiro
Nishizawa, Toshihiro
Kikuchi, Masahiro
Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
title Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
title_full Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
title_fullStr Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
title_full_unstemmed Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
title_short Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
title_sort clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667383/
https://www.ncbi.nlm.nih.gov/pubmed/31379418
http://dx.doi.org/10.3164/jcbn.18-117
work_keys_str_mv AT morihideki clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT suzukihidekazu clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT hiraiyuichiro clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT okuzawaanna clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT kayashimaatsuto clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT kubosawayoko clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT kinoshitasatoshi clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT fujimotoai clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT nakazatoyoshihiro clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT nishizawatoshihiro clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide
AT kikuchimasahiro clinicalfeaturesofhypermagnesemiainpatientswithfunctionalconstipationtakingdailymagnesiumoxide